Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SPR | P35270 | 6/20 | 0.36 |
| ▸ | L3MBTL3 | Q96JM7 | 3/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.35 |
| ▸ | DPP4 | P27487 | 7/20 | 0.34 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.34 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.34 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18702242 | 0.92 | SPR (0.39) | SPRL3MBTL3L3MBTL1DPP4DPP7 | |
| SCHEMBL18702241 | 0.92 | L3MBTL3 (0.39) | SPRL3MBTL3L3MBTL1DPP4DPP8 | |
| SCHEMBL18702038 | 0.90 | SPR (0.34) | SPRL3MBTL3L3MBTL1DPP4DPP8 | |
| SCHEMBL14804544 | 0.84 | DPP4 (0.44) | DPP4DPP8DPP9DPP7 | |
| SCHEMBL18307613 | 0.84 | DPP4 (0.44) | DPP4DPP8DPP9DPP7 | |
| SCHEMBL13002662 | 0.84 | DPP4 (0.44) | DPP4DPP8DPP9DPP7 | |
| SCHEMBL26252044 | 0.84 | MGLL (0.38) | L3MBTL3L3MBTL1DPP4DPP8DPP7 | |
| SCHEMBL26254614 | 0.83 | L3MBTL3 (0.39) | L3MBTL3L3MBTL1DPP4 | |
| SCHEMBL18702296 | 0.83 | SPR (0.37) | SPRL3MBTL3L3MBTL1DPP4DPP7 | |
| SCHEMBL18702298 | 0.81 | L3MBTL3 (0.34) | SPRL3MBTL3L3MBTL1DPP4DPP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230265103-A1 | NOVEL INHIBITORS OF PIKFYVE AND METHODS USING SAME | TME THERAPEUTICS LLC | 2023-08-24 | — | — | US | disclosed |
| US-9963462-B2 | Sepiapterin reductase inhibitors | MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V. (DE) | 2018-05-08 | — | — | US | disclosed |
| US-20170096435-A1 | SEPIAPTERIN REDUCTASE INHIBITORS | MAX-PLANCK-GESELLSCHAFT ZUR FOERDERUNG DER WISSENSCHAFTEN E.V. (DE) | 2017-04-06 | — | — | US | disclosed |
| US-20170096435-A1 | SEPIAPTERIN REDUCTASE INHIBITORS | MAX-PLANCK-GESELLSCHAFT ZUR FOERDERUNG DER WISSENSCHAFTEN E.V. (DE) | 2017-04-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230265103-A1 | NOVEL INHIBITORS OF PIKFYVE AND METHODS USING SAME | PIKFYVE, PIK3CD, PIK3R5 | SPR 4518/4885L3MBTL3 4275/4885L3MBTL1 4350/4885 |
| US-20170096435-A1 | SEPIAPTERIN REDUCTASE INHIBITORS | SPR, QDPR, SRR | SPR 1/4885L3MBTL3 2777/4885L3MBTL1 1901/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.